MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/rheumatology/keae532

Медицинская библиотека · Rheumatology (Oxford, England) · 2025

Long-term retention rate, adverse event temporal patterns and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life.

De Lorenzis Enrico, Natalello Gerlando, Pellegrino Greta, Verardi Lucrezia, Batani Veronica, Lepri Gemma, Stano Stefano, Armentano Giuseppe, De Pinto Marco, Motta Francesca, Di Donato Stefano, Kakkar Vishal, Fiore Silvia, Bisconti Ilaria, Campochiaro Corrado, Cometi Laura, Tonutti Antonio, Spinella Amalia, Truglia Simona, Cavalli Silvia, De Santis Maria, Giuggioli Dilia, Del Papa Nicoletta, Guiducci Serena, Cacciapaglia Fabio, De Luca Giacomo, Iannone Fiorenzo, Ricceri Valeria, Matucci Cerinic Marco, D'Agostino Maria Antonietta, Del Galdo Francesco, Bosello Silvia Laura

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

MMF is a mainstay for the treatment of SSc. The occurrence and implications of MMF-related adverse events (AEs) on drug retention rates in real life remain poorly defined. We aimed to determine the MMF retention rate and to investigate the causes and patterns of discontinuation, AEs and treatment options used after discontinuation.

METHODS

SSc patients who started MMF treatment underwent a retrospective longitudinal assessment for up to 5 years. We documented the incidence, predictors and impacts of MMF treatment on gastrointestinal intolerance, infections, laboratory abnormalities and cancer. Rescue strategies implemented after MMF discontinuation were recorded.

RESULTS

The 5-year MMF retention rate of 554 patients stood at 70.7%, and 19.6% of them stopped MMF due to AEs. One out of every four patients experienced a dose reduction or discontinuation of MMF due to AEs, with gastrointestinal intolerance being the predominant cause. The 5-year cumulative incidence rates for gastrointestinal intolerance, cancer, severe infections and laboratory toxicity leading to MMF discontinuation were 6.4%, 4.1%, 3.1% and 2.1%, respectively. Lower respiratory tract was the most affected, with bacteria being the predominant causative agent. Intestinal and pulmonary circulation involvement were tied to elevated AE rates and MMF discontinuation. The most common approaches post-MMF cessation were 'watch and wait' and switch to rituximab.

CONCLUSIONS

: MMF use in SSc appears to be limited by the occurrence of AEs, both in terms of persistence and dosing of the drug. Rescue options after MMF discontinuation are limited and many patients remain without immunosuppressant.

Для цитирования: De Lorenzis Enrico, Natalello Gerlando, Pellegrino Greta, Verardi Lucrezia, Batani Veronica, Lepri Gemma, Stano Stefano, Armentano Giuseppe, De Pinto Marco, Motta Francesca, Di Donato Stefano, Kakkar Vishal, Fiore Silvia, Bisconti Ilaria, Campochiaro Corrado, Cometi Laura, Tonutti Antonio, Spinella Amalia, Truglia Simona, Cavalli Silvia, De Santis Maria, Giuggioli Dilia, Del Papa Nicoletta, Guiducci Serena, Cacciapaglia Fabio, De Luca Giacomo, Iannone Fiorenzo, Ricceri Valeria, Matucci Cerinic Marco, D'Agostino Maria Antonietta, Del Galdo Francesco, Bosello Silvia Laura. Long-term retention rate, adverse event temporal patterns and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life.. Rheumatology (Oxford, England). 2025. DOI: 10.1093/rheumatology/keae532.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.